Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]

Laidlaw TM, Menzies-Gow A, Caveney S, et al. J Asthma Allergy. 2023;16:915–932. The authors have advised there is an error in Figure 1 on page 922. The n= x-axis data were transposed for the treatment groups for both the Patients with NPs and Patients without NPs. The correct Figure 1 is...

Full description

Bibliographic Details
Published in:Journal of Asthma and Allergy
Main Authors: Laidlaw TM, Menzies-Gow A, Caveney S, Han JK, Martin N, Israel E, Lee JK, Llanos JP, Megally A, Parikh B, Vong S, Welte T, Corren J
Format: Article
Language:English
Published: Dove Medical Press 2023-09-01
Subjects:
chronic rhinosinusitis
nasal polyps
snot-22
thymic stromal lymphopoietin
Online Access:https://www.dovepress.com/corrigendum-tezepelumab-efficacy-in-patients-with-severe-uncontrolled--peer-reviewed-fulltext-article-JAA
Description
Summary:Laidlaw TM, Menzies-Gow A, Caveney S, et al. J Asthma Allergy. 2023;16:915–932. The authors have advised there is an error in Figure 1 on page 922. The n= x-axis data were transposed for the treatment groups for both the Patients with NPs and Patients without NPs. The correct Figure 1 is as follows. Figure 1 AAER over 52 weeks in patients with or without nasal polyps in the 2 years before randomization in the NAVIGATOR study.Abbreviations: AAER, annualized asthma exacerbation rate; CI, confidence interval; NP, nasal polyp; Q4W, every 4 weeks.Note: n, number of patients contributing to the analysis. The authors apologize for this error.
ISSN:1178-6965

Similar Items